Trial Profile
The clinical impact of crizotinib on central nervous system progression in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2017
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Nov 2017 New trial record